Objective： To assess the efficacy and safety of Zhongyan-4 （中研-4号, ZY-4, a Chinese herbal preparation worked out according to the therapeutic principle of supplementing qi, nourishing Yin, clearing heat and detox...Objective： To assess the efficacy and safety of Zhongyan-4 （中研-4号, ZY-4, a Chinese herbal preparation worked out according to the therapeutic principle of supplementing qi, nourishing Yin, clearing heat and detoxication） in treating HIV/AIDS patients in the early or middle stage. Methods： Adopted was randomized double-blinded and placebo-parallel-controlled method, with 72 HIV/AIDS patients randomly divided into the ZY-4 group （36 patients） treated with ZY-4 and the control group （36 patients） treated with placebo. The treatment course was six months. The index of OD4^＋, OD8^＋ counts, body weight, clinical symptom scoring were estimated at 4 time points （0, 1, 3 and 6 month in the course）, and also the viral load before and after treatment. The whole course of observation was completed in 63 patients, 30 in the ZY-4 group and 33 in the control group. Results： OD4^＋ count in the ZY-4 group got elevated by 7.70 4±150.96/mm^3 on average, while that in the control group lowered by 27.33 4±85.28 /mm^3 . Fifteen out of the 30 patients in the ZY-4 group had their OD4^＋ count increased, which was evidently much higher than that in the control group （8/33, P〈0. 05）, suggesting that the efficacy of ZY-4 is superior to that of placebo in elevating OD4^＋ count. Moreover, ZY-4 showed actions in elevating OD45RA^＋ and OD8^＋ count, reducing HIV virus load, improving clinical symptom/sign and increasing body weight of patients. No obvious adverse reaction was found in the clinical trial. Conclusion： ZY-4 has an immunity-protective and/or rebuilding function in HIV/AIDS patients in the early and middle stage, and also shows effects in lowering viral load, increasing body weight and improving symptoms and signs to a certain degree.展开更多
Objective: To investigate the curative effect of Zhongyan No. II (ZY II ) in treating SIVmac251 infection in macaques monkeys and evaluate the anti-viral effect of the drug as well as its protection on organism. Metho...Objective: To investigate the curative effect of Zhongyan No. II (ZY II ) in treating SIVmac251 infection in macaques monkeys and evaluate the anti-viral effect of the drug as well as its protection on organism. Methods: Using SIVmac251 infected monkey model to detect the plasma SIVP 27 antigen level by viral isolation and ELISA; determine the T-lymphocyte subsets CD4 and CD8 by indirect immunofluorescence and flow cytometry, and investigate the serum content of neopterin and B2-mi-croglobulin B2-MG)by ELISA. The pathological examination was conducted as well. Results: ZY II展开更多
Fan Zhongyan was a very poor student when he was a child.But he wasn't concentrate on this.He spent all of his time on study.However,he was so poor that he couldn't learn at school.So,he decided to teach himself.
基金Supported by the Projects of Ministry of Science and Tech-nology for 10th Five-year Plan (2001BA701A18)
文摘Objective： To assess the efficacy and safety of Zhongyan-4 （中研-4号, ZY-4, a Chinese herbal preparation worked out according to the therapeutic principle of supplementing qi, nourishing Yin, clearing heat and detoxication） in treating HIV/AIDS patients in the early or middle stage. Methods： Adopted was randomized double-blinded and placebo-parallel-controlled method, with 72 HIV/AIDS patients randomly divided into the ZY-4 group （36 patients） treated with ZY-4 and the control group （36 patients） treated with placebo. The treatment course was six months. The index of OD4^＋, OD8^＋ counts, body weight, clinical symptom scoring were estimated at 4 time points （0, 1, 3 and 6 month in the course）, and also the viral load before and after treatment. The whole course of observation was completed in 63 patients, 30 in the ZY-4 group and 33 in the control group. Results： OD4^＋ count in the ZY-4 group got elevated by 7.70 4±150.96/mm^3 on average, while that in the control group lowered by 27.33 4±85.28 /mm^3 . Fifteen out of the 30 patients in the ZY-4 group had their OD4^＋ count increased, which was evidently much higher than that in the control group （8/33, P〈0. 05）, suggesting that the efficacy of ZY-4 is superior to that of placebo in elevating OD4^＋ count. Moreover, ZY-4 showed actions in elevating OD45RA^＋ and OD8^＋ count, reducing HIV virus load, improving clinical symptom/sign and increasing body weight of patients. No obvious adverse reaction was found in the clinical trial. Conclusion： ZY-4 has an immunity-protective and/or rebuilding function in HIV/AIDS patients in the early and middle stage, and also shows effects in lowering viral load, increasing body weight and improving symptoms and signs to a certain degree.
文摘Objective: To investigate the curative effect of Zhongyan No. II (ZY II ) in treating SIVmac251 infection in macaques monkeys and evaluate the anti-viral effect of the drug as well as its protection on organism. Methods: Using SIVmac251 infected monkey model to detect the plasma SIVP 27 antigen level by viral isolation and ELISA; determine the T-lymphocyte subsets CD4 and CD8 by indirect immunofluorescence and flow cytometry, and investigate the serum content of neopterin and B2-mi-croglobulin B2-MG)by ELISA. The pathological examination was conducted as well. Results: ZY II
文摘Fan Zhongyan was a very poor student when he was a child.But he wasn't concentrate on this.He spent all of his time on study.However,he was so poor that he couldn't learn at school.So,he decided to teach himself.
